Dr. Zografidis, the Vice President Clinical Operations of Anavex®, has over 25 years of experience in the pharmaceutical and healthcare industry, including 12 years at Wyeth (now Pfizer) in clinical project management and prior to joining Anavex® most recently served as clinical and pharmaceutical consultant.  He has been involved in more than a dozen clinical trials and has co-authored numerous publications.  At Wyeth, Dr. Zografidis spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds.  His work resulted in increased sales and he received several clinical awards for his accomplishments.  Dr. Zografidis first joined Wyeth in 1998 as a Product Manager.  During his tenure until 2010, he had increased responsibility as Medical Liaison for the transplantation, haemophilia and oncology divisions where he was instrumental in driving sales in assigned European territories. Dr. Zografidis, the Vice President Clinical Operations of Anavex®, has over 25 years of experience in the pharmaceutical and healthcare industry, including 12 years at Wyeth (now Pfizer) in clinical project management and prior to joining Anavex® most recently served as clinical and pharmaceutical consultant.  He has been involved in more than a dozen clinical trials and has co-authored numerous publications.  At Wyeth, Dr. Zografidis spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds.  His work resulted in increased sales and he received several clinical awards for his accomplishments.  Dr. Zografidis first joined Wyeth in 1998 as a Product Manager.  During his tenure until 2010, he had increased responsibility as Medical Liaison for the transplantation, haemophilia and oncology divisions where he was instrumental in driving sales in assigned European territories.

Biotechnology